Literature DB >> 22257710

Comparison of outcome of higher versus lower transvalvular gradients in patients with severe aortic stenosis and low (<40%) left ventricular ejection fraction.

Itsik Ben-Dor1, Gabriel Maluenda, Getachew D Iyasu, Ana Laynez-Carnicero, Camille Hauville, Rebecca Torguson, Petros Okubagzi, Zhenyi Xue, Steven A Goldstein, Joseph Lindsay, Lowell F Satler, Augusto D Pichard, Ron Waksman.   

Abstract

Left ventricular systolic dysfunction in patients with severe aortic stenosis (AS) is associated with poor outcome. This analysis was designed primarily to describe the clinical course of a large series of consecutive patients with severe AS and low ejection fraction (EF) (<40%) who, because of high surgical risk, were referred for transcatheter aortic valve implantation consideration. A cohort of 270 patients with severe AS and low EF (<40%) who were referred to participate in a clinical trial of transcatheter aortic valve implantation was studied. Clinical, hemodynamic, and periprocedural complications and follow-up mortality data were collected and compared between patients with low mean transvalvular gradients (≤40 mm Hg, n = 170 [63%]) and high transvalvular gradients (>40 mm Hg, n = 100 [37%]). Patients with low gradients were younger (mean age 79.8 ± 9.1 vs 83.8 ± 7.7 years, p <0.001) and had higher incidences of coronary artery disease and renal failure. Mean aortic valve area was larger (0.73 ± 0.23 vs 0.53 ± 0.18 cm(2), p <0.001), while mean EF (26.4 ± 6.9% vs 30.5% ± 6.6%, p <0.001), cardiac output (3.7 ± 1.1 vs 4.1 ± 1.3 L/min, p = 0.04), and cardiac index (1.9 ± 0.5 vs 2.1 ± 0.6 L/min/m(2), p = 0.04) were lower in patients with lower gradients compared to those with higher gradients, respectively. Mortality was higher in patients with low gradients (53.8%) at a mean follow-up of 151 days compared to those with high gradients (41%) at a mean follow-up of 256 days (p = 0.01). In conclusion, patients with severe AS and low EF with low transvalvular gradients are at higher risk for worse outcomes compared to patients with high transvalvular gradients. Surgery or transcatheter aortic valve implantation treatment and high baseline transvalvular gradient are associated with EF improvement. Copyright Â
© 2012. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22257710     DOI: 10.1016/j.amjcard.2011.11.041

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

Review 1.  Low-flow/low-gradient aortic stenosis-Still a diagnostic and therapeutic challenge.

Authors:  Anja Vogelgesang; Gerd Hasenfuss; Claudius Jacobshagen
Journal:  Clin Cardiol       Date:  2017-05-23       Impact factor: 2.882

Review 2.  Efficacy of transcatheter aortic valve implantation in patients with aortic stenosis and reduced LVEF. A systematic review.

Authors:  X Luo; Z Zhao; H Chai; C Zhang; Y Liao; Q Li; Y Peng; W Liu; X Ren; Q Meng; C Chen; M Chen; Y Feng; D Huang
Journal:  Herz       Date:  2015-02-26       Impact factor: 1.443

Review 3.  Low-gradient aortic stenosis.

Authors:  Marie-Annick Clavel; Julien Magne; Philippe Pibarot
Journal:  Eur Heart J       Date:  2016-03-31       Impact factor: 29.983

4.  Impact of Ejection Fraction and Aortic Valve Gradient on Outcomes of Transcatheter Aortic Valve Replacement.

Authors:  Suzanne J Baron; Suzanne V Arnold; Howard C Herrmann; David R Holmes; Wilson Y Szeto; Keith B Allen; Adnan K Chhatriwalla; Sreekaanth Vemulapali; Sean O'Brien; Dadi Dai; David J Cohen
Journal:  J Am Coll Cardiol       Date:  2016-05-24       Impact factor: 24.094

5.  Impact of severe left ventricular dysfunction on mid-term mortality in elderly patients undergoing transcatheter aortic valve implantation.

Authors:  Giuseppe Ferrante; Patrizia Presbitero; Paolo Pagnotta; Anna Sonia Petronio; Nedy Brambilla; Federico De Marco; Claudia Fiorina; Cristina Giannini; Fabrizio D'Ascenzo; Silvio Klugmann; Marco L Rossi; Federica Ettori; Francesco Bedogni; Luca Testa
Journal:  J Geriatr Cardiol       Date:  2016-05       Impact factor: 3.327

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.